PubMed:28854065 / 381-570 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/28854065","sourcedb":"PubMed","sourceid":"28854065","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/28854065","text":"Patients and Methods In a randomized, double-blind, active-controlled, phase III trial, chemotherapy-naive patients with cancer who were scheduled to receive HEC that contained cisplatin or","tracks":[{"project":"PubMed_ArguminSci","denotations":[{"id":"T2","span":{"begin":0,"end":189},"obj":"DRI_Background"}],"attributes":[{"subj":"T2","pred":"source","obj":"PubMed_ArguminSci"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"PubMed_ArguminSci","color":"#ecde93","default":true}]}]}}